glp-1 agonist alzheimer's Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and Dementia in Diabetes Mellitus The promise and peril of
Description
doi:10.1210/jcem-24-10-1076 181

There's no guarantee it will continue after 2027

What's more, the GLP-1 Companion has high daily-to-monthly usage ratios, reflecting a level of engagement more on par with a social application than a behavior change program

[1] These medicines include semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and exenatide (Byetta, Bydureon)
WashU Medicines findings also showed a decreased risk of neurocognitive disorders such as Alzheimers and dementia
